Elevance Health stock gains as FY 2026 EPS guidance trails consensus
Published on 09/20/2026 at 12:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health Inc. (ISIN US0367521038) stock is trading close to USD 410.95 on the New York Stock Exchange as of September 18, 2026, keeping the managed care provider near its recent highs even after the company issued FY 2026 earnings guidance that slightly undercut analyst consensus estimates.
FY 2026 EPS guidance comes in just below consensus
According to MarketBeat on September 19, 2026, Elevance Health issued FY 2026 earnings per share guidance of USD 27.00, a touch below the analyst consensus estimate of USD 27.16 for the period.
The same guidance update highlighted that no formal revenue guidance was provided for FY 2026, leaving the top-line outlook more open while giving investors a precise EPS range to work with, and analysts as a group currently expect the company to deliver around USD 27.18 EPS for the full year 2026, a marginally higher figure than the company’s own guidance.
Q2 2026 results beat expectations on earnings and revenue
As detailed by MarketBeat, Elevance Health last reported quarterly results on July 15, 2026, posting EPS of USD 7.45 for the quarter, which beat the consensus estimate of USD 6.21 by USD 1.24 per share.
In the same quarter, Elevance Health generated revenue of USD 49.83 billion, slightly ahead of the analyst expectation of USD 48.88 billion by USD 0.95 billion, with the company’s revenue up 0.8 percent year on year, while net margin stood at 2.47 percent and return on equity reached 14.64 percent for the period, underlining the insurer’s ability to convert a vast premium base into consistent profits.
Dividend policy adds income component for shareholders
According to MarketBeat, Elevance Health also announced a quarterly dividend of USD 1.72 per share alongside the July 15, 2026, earnings release, corresponding to an annualized payout of USD 6.88 and a dividend yield of approximately 1.7 percent at prevailing share prices.
Further dividend schedule details from StockAnalysis show that the latest ex-dividend date for Elevance Health stock was September 10, 2026, with the corresponding USD 1.72 cash dividend payable on September 25, 2026, giving investors a near-term cash flow and reinforcing Elevance Health’s profile as a managed care stock that combines earnings growth with regular shareholder returns.
Analyst view: moderate buy rating and upside to targets
As summarized by Ad-hoc-news citing MarketBeat data on September 19, 2026, Elevance Health stock carries a consensus rating of Moderate Buy, with fifteen analysts assigning a Buy recommendation and eight rating the shares Hold, indicating broadly positive sentiment without being excessively bullish.
The same overview notes that the consensus 12 month price target for Elevance Health stock stands at USD 440.90, roughly USD 30 above the recent trading zone around USD 410, which implies potential upside in the single-digit percent range from current levels if the company can deliver on its EPS guidance and maintain steady revenue growth.
Stock trades just below recent highs ahead of next earnings
Per recent price data from Investing.com, Elevance Health stock closed at USD 410.95 on the New York Stock Exchange on September 18, 2026, after trading in a daily range between USD 406.38 and USD 415.36 and ending the session down 0.80 percent from the prior close of USD 414.26.
The same historical data show that Elevance Health shares were changing hands at USD 393.20 three months earlier, meaning the stock has gained approximately 4.5 percent over the last three months to reach USD 410.95 as of September 18, 2026, while trading volumes around 2.08 million shares on that date underscore continued investor interest in the managed care name.
Next earnings date and sector backdrop
Looking ahead, AltIndex points out on September 20, 2026, that Elevance Health is scheduled to report its next quarterly earnings on October 19, 2026, with the consensus EPS estimate for that print currently at USD 6.18 per share and the platform’s AI score assigning Elevance Health a mixed signal rating of 68 out of 100.
The broader healthcare space has attracted investor interest recently, with data from Outlook Money on September 20, 2026, indicating that foreign portfolio investors moved money into healthcare stocks during the first half of September, and a regional healthcare index posted gains of around 17.69 percent over six months versus roughly 1 percent for the broader market, underscoring a supportive sector backdrop for Elevance Health.
Closing price snapshot for Elevance Health stock
Elevance Health stock closed at USD 410.95 on the New York Stock Exchange on September 18, 2026, with an intraday range between USD 406.38 and USD 415.36 and a trading volume of 2.08 million shares, leaving the managed care group’s market capitalization around USD 89.9 billion and positioning the stock modestly below its recent highs as investors digest the slightly conservative FY 2026 EPS guidance.
Elevance Health stock key data
- Company: Elevance Health Inc.
- ISIN: US0367521038
- Ticker: ELV
- Trading venue: NYSE
- Price (as of September 18, 2026): 410.95 USD
- Market capitalization: 89.86 billion USD (as of September 18, 2026)
- Sector / Industry: Health Care / Managed Care
- Index membership: S&P 500
- Next earnings date: October 19, 2026
